ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway

BMB Rep. 2019 Jul;52(7):457-462. doi: 10.5483/BMBRep.2019.52.7.042.

Abstract

[18F]Fluorodeoxyglucose (FDG) PET/CT imaging has been widely used in the diagnosis of malignant tumors. ATPase family AAA domain-containing protein 2 (ATAD2) plays important roles in tumor growth, invasion and metastasis. However, the relationship between [18F]FDG accumulation and ATAD2 expression remains largely unknown. This study aimed to investigate the correlation between ATAD2 expression and [18F]FDG uptake in lung adenocarcinoma (LUAD), and elucidate its underlying molecular mechanisms. The results showed that ATAD2 expression was positively correlated with maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), glucose transporter type 1 (GLUT1) expression and hexokinase2 (HK2) expression in LUAD tissues. In addition, ATAD2 knockdown significantly inhibited the proliferation, tumorigenicity, migration, [18F]FDG uptake and lactate production of LUAD cells, while, ATAD2 overexpression exhibited the opposite effects. Furthermore, ATAD2 modulated the glycometabolism of LUAD via AKT-GLUT1/HK2 pathway, as assessed using LY294002 (an inhibitor of PI3K/AKT pathway). In summary, to explore the correlation between ATAD2 expression and glycometabolism is expected to bring good news for anti-energy metabolism therapy of cancers. [BMB Reports 2019; 52(7): 457-462].

Publication types

  • News

MeSH terms

  • ATPases Associated with Diverse Cellular Activities / antagonists & inhibitors
  • ATPases Associated with Diverse Cellular Activities / genetics
  • ATPases Associated with Diverse Cellular Activities / metabolism*
  • Adenocarcinoma of Lung / drug therapy
  • Adenocarcinoma of Lung / metabolism*
  • Adenocarcinoma of Lung / pathology
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Chromones / pharmacology
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism*
  • Dose-Response Relationship, Drug
  • Female
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Glucose Transporter Type 1 / antagonists & inhibitors
  • Glucose Transporter Type 1 / metabolism
  • Hexokinase / antagonists & inhibitors
  • Hexokinase / metabolism
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Morpholines / pharmacology
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism

Substances

  • Chromones
  • DNA-Binding Proteins
  • Glucose Transporter Type 1
  • Morpholines
  • SLC2A1 protein, human
  • Fluorodeoxyglucose F18
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • HK2 protein, human
  • Hexokinase
  • Proto-Oncogene Proteins c-akt
  • ATAD2 protein, human
  • ATPases Associated with Diverse Cellular Activities